Testing whether CGRP can trigger migraine aura in adults
Tests whether CGRP, a migraine-related peptide, triggers aura in adults with migraine.
Plain-language title generated from the registry record
Registry title: Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide
Key facts
- Where
- Glostrup Municipality, DenmarkSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07021859, who can take part
Where in Denmark
- Rigshospitalet GlostrupGlostrup Municipality, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Danish Headache Center
- Trial code
- NCT07021859
- Record updated
- 6 August 2025
- Original description
Calcitonin gene-related peptide (CGRP) is a key neuropeptide in migraine pathophysiology and treatment. This study investigates whether CGRP administration can trigger aura in individuals with a diagnosis of migraine with aura.Read full original descriptionShow less
Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide: A Randomized Clinical Trial
Calcitonin gene-related peptide (CGRP) is a key neuropeptide in migraine pathophysiology and treatment. This study investigates whether CGRP administration can trigger aura in individuals with a diagnosis of migraine with aura.
Inclusion: Age 18 to 65 years of age upon entry into screening; History of migraine with aura for ≥ 12 months according to the International Classification of Headache Disorders 3rd Edition (ICHD-3) criteria; ≥ 1 monthly day with aura that meets criteria as aura on average across the three months before screening; Provision of informed consent prior to initiation of any study-specific activities/procedures.
Exclusion: Hypertension (systolic blood pressure of ≥150 mmHg and/or diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day; Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion; Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start; Any history of a primary or secondary headache disorder other than migraine without aura, migraine with aura, chronic migraine, and episodic tension-type headache; History or evidence of any other clinically significant disorder, condition, or disease (except for those outlined above) that, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion; Cardiovascular disease of any kind, including cerebrovascular diseases; The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior; Female subjects of childbearing potential with a positive pregnancy test during any study visit; Hypotension (systolic blood pressure of ≤90 mmHg and/or diastolic blood pressure of ≤50 mmHg); Headache of any intensity within 48 hours of infusion start; Aura within 48 hours of infusion start.